drugset / Trial / NCT06182592
A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this bridging study is to determine the efficacy of liposomal cytarabine-daunorubicin for injection compared with cytarabine and daunorubicin in older patients with high-risk (secondary) acute myeloid leukemia.
Timeline
- Start
- 2024-01
- Primary completion
- 2026-02
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Daunorubicin | Small molecule | 60 mg/m2 | — |
| Subject | Liposomal cytarabine-daunorubicin for injection | Small molecule | 100 unknown | Intravenous |